AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31927647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 20
Study 29231133 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib, melphalan, and prednisone
Number of subjects: 706
Study 29231133 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib, melphalan, and prednisone (control group)
Number of subjects: 706
Study 27002662 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) treatment
Number of subjects: 41
Study 27002662 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) including active stretching, ROM and pendulum exercises
Number of subjects: 41
Study 25487477 — intervention group
Group type: EXPERIMENTAL
Intervention: Single shot bilateral intercostal block with levobupivacaine (L group)
Number of subjects: 60
Study 25487477 — intervention group
Group type: COMPARATOR
Intervention: 0.9 % saline (S group)
Number of subjects: 60
Study 22502849 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based motor, perceptual and cognitive training for 30 min each day for 20 weeks
Number of subjects: 40
Study 22502849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study 19816834 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative exposure therapy (NET)
Number of subjects: 32
Study 19816834 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 32
Study 18555862 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RH)
Number of subjects: 205
Study 18555862 — intervention group
Group type: COMPARATOR
Intervention: Total hip arthroplasty (THA)
Number of subjects: 205
Study 16024479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received additional support from a social worker for goal setting, motivation, and planning for return to work.
Number of subjects: 184
Study 16024479 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control) did not receive additional support from a social worker.
Number of subjects: 184
Study 16024479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 184
Study 16024479 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 184
Study 12236631 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 100
Study 12236631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg)
Number of subjects: 100
Study 12236631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10438552 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) plus standard medical treatment
Number of subjects: 120
Study 10438552 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 120
Study 10438552 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120
Study 10438552 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study 8526835 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of absolute bed rest
Number of subjects: 5
Study 2170921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconit
Number of subjects: 50
Study 2170921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 727631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 21
Study 727631 — intervention group
Group type: COMPARATOR
Intervention: Iodoxouridine (IDU)
Number of subjects: 21
Study 30143002 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 93
Study 30143002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 93
Study 30143002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Physical And Cognitive Training (PACT)
Number of subjects: 93
Study 30143002 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Group (WG)
Number of subjects: 93
Study 27116462 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 80
Study 27116462 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 80
Study 27116462 — intervention group
Group type: COMPARATOR
Intervention: Placebo lubricant
Number of subjects: 80
Study 25294621 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - supervised resistance training to arm and hip extensors on 3 days a week with additional 2 days a week of light walking
Number of subjects: 13
Study 25294621 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UC) - participated in usual activities provided within their living facility
Number of subjects: 13
Study 22367982 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity scheduling
Number of subjects: 597
Study 20586748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular local anaesthesia with 20 ml ropivacaine 0.5%
Number of subjects: 60
Study 20586748 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular local anaesthesia with 20 ml ropivacaine 0.5%
Number of subjects: 60
Study 17095133 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 27
Study 17095133 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture intervention
Number of subjects: 27
Study 16321179 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7510
Study 16321179 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 7510
Study 16321179 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 7510
Study 16321179 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of reperfusion therapy
Number of subjects: 7510
Study 16321179 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome (all-cause mortality, re-infarction, stroke within 7 days)
Number of subjects: 7510
Study 16321179 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality within 30 days
Number of subjects: 7510
Study 11904788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 24 mg once daily
Number of subjects: 92
Study 11904788 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg three times daily
Number of subjects: 92
Study 11904788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 10603633 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum (IS) technique
Number of subjects: 0
Study 10603633 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 0
Study 7725560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound scanning (TRUS)
Number of subjects: 61
Study 7725560 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 61
Study 2047061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal prostaglandin E2 (PGE2) gel (2.0 mg, twice-weekly)
Number of subjects: 50
Study 2047061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6996112 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation during pregnancy
Number of subjects: 0
Study 6996112 — intervention group
Group type: COMPARATOR
Intervention: No iron or intermittent iron supplement
Number of subjects: 0
Study 6996112 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-treated mothers
Number of subjects: 0
Study 6996112 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (untreated mothers)
Number of subjects: 0
Study 30355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide depot/autogel 120 mg
Number of subjects: 171
Study 30355775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 27762088 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT plus 50 mg ipragliflozin
Number of subjects: 58
Study 27762088 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT plus 50 mg ipragliflozin and 20 mg teneligliptin
Number of subjects: 58
Study 27762088 — intervention group
Group type: COMPARATOR
Intervention: BBT alone
Number of subjects: 58
Study 25913905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 67
Study 25913905 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 67
Study 24359311 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure seal alone (Group 3)
Number of subjects: 0
Study 24359311 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure seal with oversewing (Group 4)
Number of subjects: 0
Study 24359311 — intervention group
Group type: COMPARATOR
Intervention: Staple line intact (Group 1)
Number of subjects: 0
Study 24359311 — intervention group
Group type: COMPARATOR
Intervention: Staple line oversewn (Group 2)
Number of subjects: 0
Study 22844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied carbohydrate (CL, peach blended in 500 ml water + 250 ml water)
Number of subjects: 10
Study 22844543 — intervention group
Group type: COMPARATOR
Intervention: Solid carbohydrate (CS, whole peaches + 750 ml water)
Number of subjects: 10
Study 22844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied carbohydrate (CL)
Number of subjects: 10
Study 22844543 — intervention group
Group type: COMPARATOR
Intervention: Solid carbohydrate (CS)
Number of subjects: 10
Study 19232755 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-based treatment and atorvastatin 10 mg
Number of subjects: 19342
Study 19232755 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 19342
Study 19232755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19342
Study 17465453 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 14
Study 17465453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15272513 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml ropivacaine 7.5 mg/ml
Number of subjects: 41
Study 15272513 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml ropivacaine 7.5 mg/ml
Number of subjects: 41
Study 15272513 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml ropivacaine 7.5 mg/ml (nerve block)
Number of subjects: 41
Study 15272513 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml ropivacaine 7.5 mg/ml (nerve block)
Number of subjects: 41
Study 15272513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (both dosages)
Number of subjects: 41
Study 12578906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with n‐3 polyunsaturated fatty acids (PUFAs), advised to decrease consumption of fats/oils and n‐6 PUFAs, and increase intake of n‐3 PUFAs.
Number of subjects: 0
Study 12578906 — intervention group
Group type: COMPARATOR
Intervention: Comparison group advised to reduce intake of fats/oils as a whole.
Number of subjects: 0
Study 9652426 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 1000 mg daily for 24 weeks
Number of subjects: 28
Study 1443451 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 100 micrograms in each nostril morning and evening for 4 weeks
Number of subjects: 69
Study 1443451 — intervention group
Group type: COMPARATOR
Intervention: Astemizole, one 10-mg tablet each morning for 4 weeks
Number of subjects: 69
Study 1443451 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 69
Study 1443451 — intervention group
Group type: COMPARATOR
Intervention: Astemizole
Number of subjects: 69
Study 2935051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg every 6 hr
Number of subjects: 8
Study 2935051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg every 12 hr
Number of subjects: 8
Study 2935051 — intervention group
Group type: COMPARATOR
Intervention: Control (no other treatment)
Number of subjects: 8
Study 30789775 — intervention group
Group type: EXPERIMENTAL
Intervention: CommunityRx intervention (usual care + personalized list of community resources)
Number of subjects: 411
Study 30789775 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care only)
Number of subjects: 411
Study 29228392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with no RBV for the first 2 weeks followed by weight-based dosing thereafter (Arm A)
Number of subjects: 0
Study 29228392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with weight-based RBV for all 12 weeks (Arm B)
Number of subjects: 0
Study 29228392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with low-dose RBV (600 mg) once daily for all 12 weeks (Arm C)
Number of subjects: 0
Study 26975476 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis
Number of subjects: 3527
Study 26975476 — intervention group
Group type: COMPARATOR
Intervention: No thromboprophylaxis
Number of subjects: 3527
Study 24618327 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 50
Study 24618327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive polypropylene clips applied to the breech
Number of subjects: 32028
Study 20061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Rated Troubling Symptoms for Depression (PaRTS-D) instrument
Number of subjects: 0
Study 20061962 — intervention group
Group type: EXPERIMENTAL
Intervention: PaRTS-D total score
Number of subjects: 0
Study 20061962 — intervention group
Group type: EXPERIMENTAL
Intervention: PaRTS-D global total score
Number of subjects: 0
Study 17611081 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB plus NTX
Number of subjects: 55
Study 17611081 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 55
Study 17611081 — intervention group
Group type: COMPARATOR
Intervention: NTX
Number of subjects: 55
Study 16297747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐ to 1.5‐microg/kg dose of fentanyl
Number of subjects: 110
Study 16297747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11977539 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20267 0.5 mg once daily
Number of subjects: 64
Study 11977539 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 20267 1.0 mg once daily
Number of subjects: 64
Study 9606816 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission social work intervention
Number of subjects: 0
Study 9606816 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study 7487186 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal piezoelectric lithotripsy (EPL)
Number of subjects: 70
Study 7487186 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 70
Study 2406330 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (415 pmol i.v. bolus injection followed by a 90‐min infusion to reach an overall dose of 62.25 pmol/kg body mass)
Number of subjects: 11
Study 2406330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2406330 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 11
Study 6988522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (normal or subnormal doses)
Number of subjects: 36
Study 31759466 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE program
Number of subjects: 224
Study 31759466 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 224
Study 26585908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 95
Study 26585908 — intervention group
Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 95
Study 25887095 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25mg)
Number of subjects: 63
Study 25887095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4mg)
Number of subjects: 63
Study 23348146 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg bid
Number of subjects: 120
Study 23348146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21186977 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 30
Study 21186977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19057212 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection into the prostate
Number of subjects: 0
Study 17724497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (1 g followed by 500 mg one week later)
Number of subjects: 1500
Study 17724497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 1500
Study 15492164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerumenex (10% triethanolamine polypeptide oleate‐condensate)
Number of subjects: 74
Study 15492164 — intervention group
Group type: EXPERIMENTAL
Intervention: Murine (6.5% carbamide peroxide)
Number of subjects: 74
Study 15492164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BSS Sterile Irrigating Solution)
Number of subjects: 74
Study 11710931 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen (SPF 25, UVA protection factor 14)
Number of subjects: 0
Study 11710931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B sunscreen (SPF 25, UVA protection factor 6)
Number of subjects: 0
Study 11710931 — intervention group
Group type: COMPARATOR
Intervention: Unprotected volunteers
Number of subjects: 0
Study 11710931 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen (SPF 9, UVA protection factor 9)
Number of subjects: 0
Study 11710931 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet B sunscreen (SPF 9, UVA protection factor 2)
Number of subjects: 0
Study 9272806 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in congruent dyads (pain intensity scores matched with caregivers)
Number of subjects: 78
Study 9272806 — intervention group
Group type: COMPARATOR
Intervention: Patients in non-congruent dyads (pain intensity scores differed by >10 on VAS)
Number of subjects: 78
Study 9272806 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregivers in congruent dyads
Number of subjects: 78
Study 9272806 — intervention group
Group type: COMPARATOR
Intervention: Family caregivers in non-congruent dyads
Number of subjects: 78
Study 7813167 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day for six months)
Number of subjects: 12
Study 7813167 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day for six months)
Number of subjects: 12
Study 2684107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium, 3 x 2 g/d, intravenously (n = 11)
Number of subjects: 21
Study 2684107 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G, 4 x 5 million U/d (n = 10)
Number of subjects: 21
Study 2684107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and Penicillin G
Number of subjects: 21
Study 1108695 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of cocaine dissolved in 2 ml of saline without adrenaline
Number of subjects: 45
Study 1108695 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg of cocaine
Number of subjects: 45
Study 1108695 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of cocaine
Number of subjects: 45
Study 31359734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuyanshu Capsules combined with levofloxacin hydrochloride and metronidazole for 56 days and 14 days respectively
Number of subjects: 112
Study 31359734 — intervention group
Group type: COMPARATOR
Intervention: Control group received Fuyanshu Capsules as its analogue
Number of subjects: 112
Study 28689920 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 192
Study 24849304 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemonitored cardiac rehabilitation (HTCR Group, n=75)
Number of subjects: 131
Study 24849304 — intervention group
Group type: COMPARATOR
Intervention: Outpatient-based standard cardiac rehabilitation (SCR Group, n=56)
Number of subjects: 131
Study 23381958 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-178882 100 mg single dose
Number of subjects: 14
Study 23381958 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 300 mg once a day for 13 days + ACT-178882 100 mg single dose on day 4
Number of subjects: 14
Study 23381958 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ACT-178882 alone vs. with diltiazem
Number of subjects: 14
Study 23381958 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-178882 alone
Number of subjects: 14
Study 23381958 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-178882 with diltiazem
Number of subjects: 14
Study 21690070 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% gelofusine solution at the rate of 20 ml/kg/h 30 min before the operation
Number of subjects: 40
Study 21690070 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringers solution at 4 ml/kg/h for maintenance of total blood volume
Number of subjects: 40
Study 19757979 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine)
Number of subjects: 194
Study 19757979 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine) with TCM cold pattern
Number of subjects: 194
Study 19757979 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine) with TCM hot pattern
Number of subjects: 194
Study 17288327 — intervention group
Group type: EXPERIMENTAL
Intervention: AB2/SP (All Bond 2/Duolink with self-cure)
Number of subjects: 40
Study 17288327 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLO/SP (Optibond Solo Plus Dual Cure with self-cure)
Number of subjects: 40
Study 17288327 — intervention group
Group type: COMPARATOR
Intervention: AB2/LP (All Bond 2/Duolink with light cure)
Number of subjects: 40
Study 17288327 — intervention group
Group type: COMPARATOR
Intervention: SOLO/LP (Optibond Solo Plus Dual Cure with light cure)
Number of subjects: 40